Entropy Neurodynamics

Entropy Neurodynamics DSCR

The Debt Service Coverage Ratio (DSCR) of Entropy Neurodynamics (ENP.AX) as of Nov 6, 2026 is -2.63. In the previous year, Debt Service Coverage Ratio (DSCR) was -2.30 — a change of 14.35% (lower).

DSCR

-2.63

YoY

14.35%

Last updated:

Debt Service Coverage Ratio (DSCR) of Entropy Neurodynamics is 2023 -2.63 . Debt Service Coverage Ratio (DSCR) of Entropy Neurodynamics was 2022 -2.30 . It decreases by 14.35% lower compared to the previous year.

The Entropy Neurodynamics DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2020
-7.36 AUD
Jan 1, 2021
-5.82 AUD
Jan 1, 2022
-2.30 AUD
Jan 1, 2023
-2.63 AUD
The Entropy Neurodynamics DSCR history
YEARDSCRYoY
-2.63+14.35%
-2.30-60.52%
-5.82-20.98%
-7.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Debt Service Coverage Ratio (DSCR) of Entropy Neurodynamics is -2.63 in 2023.

Debt Service Coverage Ratio (DSCR) of Entropy Neurodynamics changed from -2.30 to -2.63, representing a 14.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Entropy Neurodynamics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Entropy Neurodynamics

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Entropy Neurodynamics